NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

protein

Human DEDD2 Synthetic Peptide

PEP-0311

50 ug

US 167.00

Human DEDD2 Synthetic Peptide

PEP-0311

50 ug

US 167.00

Synthetic

purified

Human

Blocking Assay: Assay-dependent, Control: Assay-dependent

Human

-20 C

Apoptotic signals are often triggered by cell surface death receptors through protein-protein interactions mediated by conserved domains such as the death effector domain. A novel death effector domain (DED)-containing protein, DEDD2, has been recently identified. Over-expression of DEDD2 in transfected cells induces moderate apoptosis and results in substantial sensitization to apoptosis induced by Fas, TRAIL, and FADD. More recently, it has been shown that DEDD2 can bind caspase-8 and -10 in addition to FLIP but not FADD. Like the related protein DEDD, DEDD2 translocates from the cytosol to the nucleus upon induction of apoptosis, and it has been suggested that DEDD2 may target caspase-8 to the nucleus and that DEDD2 thus plays a critical role in death receptor-induced apoptosis. At least two alternatively spliced transcript variants encoding distinct isoforms have been found for DEDD2.

Liquid

Blocking Assay: Assay-dependent, Control: Assay-dependent

2410050E11Rik; death effector domain containing 2; death effector domain-containing DNA binding protein 2; death effector domain-containing DNA-binding protein 2; death effector domain-containingDNA binding protein 2; DED-containing protein FLAME-3; DEDD2; DNA-binding death effector domain-containing protein 2; FADD-like anti-apoptotic molecule 3; FLAME3; FLAME-3; PSEC0004